Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose

Positionspapier des Arbeitskreises Stammzelltherapie der Deutschen Gesellschaft für Rheumatologie

Autologous hematopoietic stem cell transplantation for systemic sclerosis

Position statement of the stem cell therapy working party of the German Society of Rheumatology

Zusammenfassung

Drei randomisierte kontrollierte Studien zur autologen hämatopoetischen Stammzelltransplantation (AHSZT) demonstrierten bei systemischer Sklerose (SSc) eine signifikante Überlegenheit hinsichtlich Überleben, Verbesserung von Hautfibrose, Lungenfunktion und Lebensqualität im Vergleich zur Standardtherapie. Die Vorteile müssen jedoch sorgfältig gegen die transplantationsassoziierten Risiken abgewogen werden. Daher hat eine Expertengruppe aus der Arbeitsgruppe „Stammzelltherapie“ der Deutschen Gesellschaft für Rheumatologie (DGRh) nun Empfehlungen zum Einsatz der AHSZT bei SSc erarbeitet. Auf Grundlage der hohen Evidenz wird die AHSZT als „Standardoption“ zur Behandlung ausgewählter SSc-Patienten bewertet. Als Kandidaten für eine AHSZT gelten Patienten mit frühzeitiger, schnell progredienter, diffus kutaner SSc mit viszeralen Manifestationen, die noch keine schwerwiegende Schädigung innerer Organe aufweisen. Eine enge Zusammenarbeit zwischen Rheumatologen und Transplantationszentren ist entscheidend für optimierte Patientenselektion und Behandlungsergebnisse.

Abstract

There have been three randomized controlled trials on autologous hematopoietic stem cell transplantation (AHSCT) in systemic sclerosis (SSc) that demonstrated significant superiority with respect to survival, improvement of cutaneous fibrosis, lung function and quality of life compared to standard treatment; however, these advantages must be carefully weighed against the transplantation-related risks. For this reason, an expert group from the stem cell therapy working party of the German Society for Rheumatology (DGRh) has now developed recommendations for the use of AHSCT in SSc. Based on the high-quality evidence, AHSCT is considered as the standard option for the treatment of selected SSc patients. Potential candidates for AHSCT are those with early, rapidly progressive, diffuse cutaneous SSc with visceral manifestations who have not yet developed severe damage to internal organs. A close cooperation between rheumatologists and transplantation centers is crucial for optimizing patient selection and treatment outcomes.

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Snowden JA, Badoglio M, Alexander T (2019) The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol 15(10):981–985

    CAS  Article  Google Scholar 

  2. 2.

    Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498–506

    CAS  Article  Google Scholar 

  3. 3.

    van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498

    Article  Google Scholar 

  4. 4.

    Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B et al (2018) Myeloablative autologous stem-cell transplantation for severe Scleroderma. N Engl J Med 378(1):35–47

    Article  Google Scholar 

  5. 5.

    Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N et al (2020) Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. https://doi.org/10.3324/haematol.2019.230128

    Article  PubMed  Google Scholar 

  6. 6.

    Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z et al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 1(27):2742–2755

    Article  Google Scholar 

  7. 7.

    Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G, Emdin M et al (2004) Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant 34(10):877–881

    CAS  Article  Google Scholar 

  8. 8.

    Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I et al (2011) Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 118(6):1693–1698

    CAS  Article  Google Scholar 

  9. 9.

    Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E et al (2007) Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109(6):2643–2548

    CAS  Article  Google Scholar 

  10. 10.

    Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M et al (2015) Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. Bone Marrow Transplant 50(5):706–714

    CAS  Article  Google Scholar 

  11. 11.

    Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K et al (1988) Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 6(5):813–818

    CAS  Article  Google Scholar 

  12. 12.

    Snarski E, Snowden JA, Oliveira MC, Simoes B, Badoglio M, Carlson K et al (2015) Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant 50(2):216–220

    CAS  Article  Google Scholar 

  13. 13.

    Dalle JH, Lucchini G, Balduzzi A, Ifversen M, Jahnukainen K, Macklon KT et al (2017) State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29–30 September 2015. Bone Marrow Transplant 52(7):1029–1035

    Article  Google Scholar 

  14. 14.

    Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897–1905

    Article  Google Scholar 

  15. 15.

    Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP et al (2019) Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis 78(9):1242–1248

    CAS  Article  Google Scholar 

  16. 16.

    Mihai C, Distler O, Gheorghiu AM, Constantin PI, Dobrota R, Jordan S et al (2019) Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology. https://doi.org/10.1093/rheumatology/kez558

    Article  PubMed  Google Scholar 

  17. 17.

    Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339

    Article  Google Scholar 

  18. 18.

    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719

    CAS  Article  Google Scholar 

  19. 19.

    Burt RK, Farge D (2018) Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer? Nat Rev Rheumatol 14(4):189–191

    Article  Google Scholar 

  20. 20.

    Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z et al (2017) Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 52(11):1495–1503

    CAS  Article  Google Scholar 

  21. 21.

    Blank N, Lisenko K, Pavel P, Bruckner T, Ho AD, Wuchter P (2016) Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol 97(1):78–82

    CAS  Article  Google Scholar 

  22. 22.

    Tyndall A, Gratwohl A (1997) Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19(7):643–645

    CAS  Article  Google Scholar 

  23. 23.

    Blank N, Lorenz HM (2013) Treatment and course of a man with systemic sclerosis before and after hematopoetic blood stem cell transplantation. Dtsch Med Wochenschr 138(37):1824–1827

    CAS  Article  Google Scholar 

  24. 24.

    Henes JC, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C et al (2014) Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology 53(5):919–922

    CAS  Article  Google Scholar 

  25. 25.

    Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD et al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380(26):2518–2528

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. T. Alexander.

Ethics declarations

Interessenkonflikt

T. Alexander, J. Henes, J. Distler, M. Schmalzing, N. Blank, I. Kötter und F. Hiepe geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

T. Alexander, Berlin

G.-R. Burmester, Berlin

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alexander, T., Henes, J., Distler, J.H.W. et al. Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose. Z Rheumatol 79, 429–436 (2020). https://doi.org/10.1007/s00393-020-00789-0

Download citation

Schlüsselwörter

  • Autologe Stammzelltransplantation
  • Systemische Sklerose
  • Zelltherapie
  • Empfehlung
  • DGRh

Keywords

  • Autologous stem cell transplantation
  • Systemic sclerosis
  • Cell therapy
  • Guidelines
  • DGRh